ROS1 fusion
A rare fusion that opens the ROS1 inhibitor category in non-small-cell lung cancer.
Parent marker: ROS1
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Clinical meaning
ROS1 fusion activates growth signaling pathways. This group is discussed with ROS1 inhibitors, including drugs that are active against brain involvement.
How this finding appears in a report
Often found in sequencing panels that include RNA or via FISH, with confirmation by orthogonal methods when necessary.
When therapy stops working
Changes in the ROS1 kinase domain and activation of the alternative pathway are part of the re-examination.
What needs verification
- Complete variant name as written in the laboratory report.
- Examination methods and types of samples used.
- Examination dates were compared with ongoing therapy.
Marker context: ROS1
ROS1 fusions make the category of ROS1/ALK inhibitors relevant for discussion in advanced non-small-cell lung cancer, depending on other findings and patient condition.
A negative result does not always mean absent
Summary
- Gen
- ROS1
- Variant
- ROS1 rearrangement
- Alteration type
- Fusion
- Discussed in
- Lung Cancer
- Updated
- 2026-09-10
Other names in reports
ROS1 fusion
Drugs discussed
Treatment categories
Sources
- NCI Dictionary of Cancer Terms(lembaga)
- ClinicalTrials.gov(registry)
Clinical trials
Studies mentioning marker ROS1
Filtered from public study descriptions. Access status and site readiness remain unverified.
NCT01639508Phase 2Combination regimen
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Lung Cancer | biomarker: ROS1, MET, RET, NTRK
United States7 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker ROS1.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT01639508Not verified
NCT06315010Phase 2Targeted therapy
Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis
Lung Cancer | biomarker: ROS1 | Targeted therapy
Austria, Germany, Spain17 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker ROS1, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06315010Not verified
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- ROS1
Biomarker
Reason: Related through a biomarker
- Lung Cancer
Cancer type
Reason: Related to this page
- Crizotinib
Drug
Reason: Related to this page
- Entrectinib
Drug
Reason: Related to this page
- Targeted therapy
Treatment category
Reason: Related to this page
- Lorlatinib
Drug
Reason: Related to this page
To check
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.